COVID-19 pandemic is expected to hamper growth of the global hypertension in CKD market during the forecast period. According to the Indian Journal of Medical Sciences, June 6, 2020, the COVID-19 pandemic has affected the conduction of clinical trials due to unavailability of trial site staff, restrictions for travelling, investigational product availability, and others. These challenges are hindrances for developing new treatment for the patients suffering from hypertension with CKD.

1. https://www.coherentmarketinsights.com

2. Table of Contents
1. Research Objectives and Assumptions
2. Market Purview
3. Market Dynamics, Regulations, and Trends Analysis
4. Europe Cable Joint Market, By Type, 2021-2028 (US$ Million)
5. Europe Cable Joint Market, By End-use Vertical, 2021-2028 (US$ Million)
6. Europe Cable Joint Market, By Country, 2021-2028 (US$ Million)
7. Competitive Landscape
8. Section
https://www.coherentmarketinsights.com

3. Report Highlights
 Chronic kidney disease (CKD) is the gradual loss of kidney function over a period of several
years. Due to kidney failure, the organ’s function is severely impaired, which leads to
accumulation of dangerous levels of waste and fluid in the body. Early detection can help
prevent the progression of kidney to kidney failure. The treatment for CKD is aimed at
stopping or slowing down the progression of the disease. Diuretics, RAS Blockade, β –
Blockers, Calcium Channel Blockers etc. are some of the major drug used for the treatment
of chronic kidney disease or its underlying cause.
 Prominent Regions-
1. Africa
2. Latin America
3. North America
4. Middle East
5. Europe
6. Asia Pacific
https://www.coherentmarketinsights.com

4. Report Highlights
 The global hypertension in CKD market is estimated to be valued at US$ 191.8 Mn in
2020 and is expected to exhibit a CAGR of 10.6% over the forecast period (2020-2027).
 Major players operating in the global hypertension in CKD market include Sanofi S.A,
Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca Plc, Novartis
International AG, C.H. Boehringer Sohn AG & Ko. KG, Kissei Pharmaceutical Co., Ltd.,
Reata Pharmaceuticals, Inc., Ardelyx, and KBP Biosciences Holdings Limited.
https://www.coherentmarketinsights.com

5. Report Highlights
 Growth Drivers-
• Increasing collaboration for conducting research and development activities
• Rising number of product launches
• Increasing prevalence of chronic kidney diseases
 Restraints & Challenges-
• Lack of awareness about chronic kidney disease
https://www.coherentmarketinsights.com

6. Reports Link
 View Full Report- https://bit.ly/3e1bBvO
 Request For Sample Copy- https://bit.ly/32TTx0D
 Download PDF Brochure- https://bit.ly/3dZkxSv
https://www.coherentmarketinsights.com

7. About
coherentmarketinsights.com
 Coherent Market Insights is a global market intelligence and consulting
organization focused on assisting our plethora of clients achieve
transformational growth by helping them make critical business decisions.
 We offer both customized and syndicated market research reports that help
our clients create visionary growth plans to provide traction to their business.
We meticulously study emerging trends across various industries at both the
global and regional levels to identify new opportunities for our clientele. Our
global team of over 100 research analysts and freelance consultants provide
market intelligence from the very molecular country level and also provide a
global perspective of the market.

8. Contact Us
Mr. Shah
Coherent Market Insights Pvt. Ltd.
Address: 1001 4th Ave, #3200 Seattle, WA 98154, United States.
Phone: +1-206-701-6702
Email- sales@coherentmarketinsights.com